Exclusive: Teva Pharm unlikely to reach deals to co-produce vaccines -CEO
Reuters
Published Apr 28, 2021 10:12AM ET
JERUSALEM (Reuters) - Israel’s Teva Pharmaceutical Industries (NYSE:TEVA) is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing, chief executive Kare Schultz told Reuters.
Schultz said Teva -- the world's largest generic drugmaker -- offered to co-produce the vaccines in both Israel and Europe, where the company has capacity, to help with global supply.
"But we've not been able to reach a firm agreement with any company," he said. "It's not for our lack of wanting to do it but the key players that have actually been successful in developing the vaccines that have come to the market have found other partners or their own internal capacity."
He did not name the companies.
"It's probably pretty much done (but) we can't rule it out," Schultz said. "We're still in discussion with some of the companies, and we're still willing to do it if we can help."
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.